Meng Yuzhong Jeff, Mankuzhy Nikhil P, Chawla Mohit, Lee Robert P, Yorke Ellen D, Zhang Zhigang, Gelb Emily, Lim Seng Boh, Cuaron John J, Wu Abraham J, Simone Charles B, Gelblum Daphna Y, Lovelock Dale Michael, Harris Wendy, Rimner Andreas
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Department of Medicine, Pulmonary Service, Section of Interventional Pulmonology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Cancers (Basel). 2024 Apr 17;16(8):1534. doi: 10.3390/cancers16081534.
Electromagnetic transponders bronchoscopically implanted near the tumor can be used to monitor deep inspiration breath hold (DIBH) for thoracic radiation therapy (RT). The feasibility and safety of this approach require further study.
We enrolled patients with primary lung cancer or lung metastases. Three transponders were implanted near the tumor, followed by simulation with DIBH, free breathing, and 4D-CT as backup. The initial gating window for treatment was ±5 mm; in a second cohort, the window was incrementally reduced to determine the smallest feasible gating window. The primary endpoint was feasibility, defined as completion of RT using transponder-guided DIBH. Patients were followed for assessment of transponder- and RT-related toxicity.
We enrolled 48 patients (35 with primary lung cancer and 13 with lung metastases). The median distance of transponders to tumor was 1.6 cm (IQR 0.6-2.8 cm). RT delivery ranged from 3 to 35 fractions. Transponder-guided DIBH was feasible in all but two patients (96% feasible), where it failed because the distance between the transponders and the antenna was >19 cm. Among the remaining 46 patients, 6 were treated prone to keep the transponders within 19 cm of the antenna, and 40 were treated supine. The smallest feasible gating window was identified as ±3 mm. Thirty-nine (85%) patients completed one year of follow-up. Toxicities at least possibly related to transponders or the implantation procedure were grade 2 in six patients (six incidences, cough and hemoptysis), grade 3 in three patients (five incidences, cough, dyspnea, pneumonia, and supraventricular tachycardia), and grade 4 pneumonia in one patient (occurring a few days after implantation but recovered fully and completed RT). Toxicities at least possibly related to RT were grade 2 in 18 patients (41 incidences, most commonly cough, fatigue, and pneumonitis) and grade 3 in four patients (seven incidences, most commonly pneumonia), and no patients had grade 4 or higher toxicity.
Bronchoscopically implanted electromagnetic transponder-guided DIBH lung RT is feasible and safe, allowing for precise tumor targeting and reduced normal tissue exposure. Transponder-antenna distance was the most common challenge due to a limited antenna range, which could sometimes be circumvented by prone positioning.
经支气管镜在肿瘤附近植入电磁应答器可用于监测胸部放射治疗(RT)中的深吸气屏气(DIBH)。这种方法的可行性和安全性需要进一步研究。
我们纳入了原发性肺癌或肺转移瘤患者。在肿瘤附近植入三个应答器,随后进行DIBH模拟、自由呼吸模拟以及作为备用的4D-CT扫描。治疗的初始门控窗口为±5毫米;在第二个队列中,逐步缩小窗口以确定最小可行门控窗口。主要终点是可行性,定义为使用应答器引导的DIBH完成放疗。对患者进行随访以评估应答器相关和放疗相关的毒性。
我们纳入了48例患者(35例原发性肺癌患者和13例肺转移瘤患者)。应答器到肿瘤的中位距离为1.6厘米(四分位间距0.6 - 2.8厘米)。放疗疗程为3至35次分割。除两名患者外,应答器引导的DIBH在所有患者中均可行(可行性为96%),这两名患者失败是因为应答器与天线之间的距离>19厘米。在其余46例患者中,6例采用俯卧位治疗以使应答器保持在天线19厘米范围内,40例采用仰卧位治疗。确定最小可行门控窗口为±3毫米。39例(85%)患者完成了一年的随访。至少可能与应答器或植入操作相关的毒性反应中,6例患者为2级(6次,咳嗽和咯血),3例患者为3级(5次,咳嗽、呼吸困难、肺炎和室上性心动过速),1例患者为4级肺炎(植入后数天发生,但完全康复并完成放疗)。至少可能与放疗相关的毒性反应中,18例患者为2级(41次,最常见的是咳嗽、疲劳和肺炎),4例患者为3级(7次,最常见的是肺炎),没有患者出现4级或更高等级的毒性反应。
经支气管镜植入电磁应答器引导的DIBH肺部放疗是可行且安全的,可实现精确的肿瘤靶向并减少正常组织受照。由于天线范围有限,应答器与天线的距离是最常见的挑战,有时可通过俯卧位来解决。